-+ 0.00%
-+ 0.00%
-+ 0.00%

Rapport Therapeutics says RAP-219 Phase 2a follow-up sustains seizure reductions in focal seizures

PUBT·04/21/2026 20:32:50
Listen to the news
Rapport Therapeutics says RAP-219 Phase 2a follow-up sustains seizure reductions in focal seizures
  • Rapport Therapeutics presented follow-up results from Phase 2a trial of RAP-219 in focal onset seizures at 2026 American Academy of Neurology Annual Meeting on April 21, 2026.
  • Data showed seizure control remained durable beyond end of dosing, with clinical outcomes holding up through 16 weeks of drug exposure.
  • Pharmacokinetic analyses supported a longer drug persistence than previously estimated, reinforcing rationale for less frequent dosing.
  • Safety profile remained broadly consistent through follow-up, with no new treatment-related serious safety signals reported.
  • Company plans to start two pivotal Phase 3 trials in focal onset seizures in Q2 2026, with initial open-label long-term safety data expected in 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211630PRIMZONEFULLFEED9694381) on April 21, 2026, and is solely responsible for the information contained therein.